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Determining lines of therapy in patients with solid cancers:
a proposed new systematic and comprehensive framework
Kamal S. Saini 1,2 and Chris Twelves 3
The complexity of neoplasia and its treatment are a challenge to the formulation of general criteria that are applicable across solid
cancers. Determining the number of prior lines of therapy (LoT) is critically important for optimising future treatment, conducting
medication audits, and assessing eligibility for clinical trial enrolment. Currently, however, no accepted set of criteria or definitions
exists to enumerate LoT. In this article, we seek to open a dialogue to address this challenge by proposing a systematic and
comprehensive framework to determine LoT uniformly across solid malignancies. First, key terms, including LoT and ‘clinical
progression of disease’ are defined. Next, we clarify which therapies should be assigned a LoT, and why. Finally, we propose
reporting LoT in a novel and standardised format as LoT N (CLoT+ PLoT), where CLoT is the number of systemic anti-cancer
therapies (SACT) administered with curative intent and/or in the early setting, PLoT is the number of SACT given with palliative
intent and/or in the advanced setting, and N is the sum of CLoT and PLoT. As a next step, the cancer research community should
develop and adopt standardised guidelines for enumerating LoT in a uniform manner.
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BACKGROUND
The treatment of solid cancers typically involves the use of
multiple modalities, such as surgery, systemic anti-cancer therapy
(SACT) and radiotherapy, alone or in combination or sequentially.
The increasing efficacy of anti-cancer therapy has resulted in
improved clinical outcomes, and it is not uncommon for a patient
with an advanced malignancy to have received successive SACTs,
often over the course of many years. Furthermore, several
different types of SACT (e.g. cytotoxic, endocrine therapy, targeted
therapy, immunotherapy and so on) are available, and are used in
different settings (e.g. adjuvant, neoadjuvant, locally advanced
and palliative). Standard treatment guidelines for patients with
advanced cancer might be lacking or non-existent, and these
patients can receive an enormous range of different treatments.
The resulting clinical pathways of real-life patients are often,
therefore, far more complex than those defined by standard
guidelines, expert opinion, consensus discussions and clinical trials
and, indeed, very few patients experience the idealised patient
pathway that is initially outlined in their care plan.1
The accurate enumeration of prior anti-cancer therapies is
critically important for a number of reasons: selecting optimal
future treatment for individual patients;2 conducting effective
medication and clinical auditing;3 determining eligibility for
enrolment into clinical trials; facilitating adherence to approved
indications; enabling more accurate health technology assess-
ment; and for the purposes of re-imbursement.4 In the era of
evidence-based medicine, it is important that prior lines of
therapy (LoT) be defined and counted in a manner that is
consistent, rational and comprehensive.
Currently, most trials and researchers refer to LoT using a single
ordinal number—for example, ‘first-line therapy’—often applied in
imprecise, confusing and conflicting ways. In the oncology
literature, the term ‘first-line therapy’ usually implies the admin-
istration of SACT to patients with unresectable advanced cancer;5
the same term may, however, also be applied to patients
receiving treatment for early cancer,6 those receiving such
therapy in an effort to render the metastatic disease resectable,7
those receiving any initial systemic therapy (irrespective of
cancer stage),8 and those receiving localised anti-cancer mod-
alities such as radiotherapy9 or highly focused ultrasound.10
Importantly, the current use of LoT makes no reference to the
total number of lines received by a given patient to date,
which may be important in situations such as patients
currently receiving ‘first-line therapy’ for metastatic breast cancer
who may have previously received multiple LoTs as (neo)adjuvant
therapy.
Defining and enumerating prior LoT is not straightforward.
Patient pathways and records, whether electronic, paper or a
mixture of the two, are often voluminous, making determination
of the LoT time-consuming, resource-intensive and error-prone.
Furthermore, as mentioned above, the implied meaning of the
term ‘LoT’ can vary, depending on the type of cancer, the
treatment intent, and definitions used in a given study protocol or
treatment guideline. Principles for determining LoT have been
proposed in patients with myeloma,11 and also in the specific
context of claims-based retrospective studies,12 the latter, how-
ever, lacks sufficient clinical context or guidelines to be widely
applied in routine practice or in clinical research. The UK Systemic
Anti-Cancer Therapy dataset incorporates treatment ‘programmes’
and ‘regimens’, numbered according to their chronological order
of commencement in the history of managing each patient’s
treatment.3 However, to the best of our knowledge, no
comprehensive guidelines exist for determining LoT across
different solid cancers.
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Several challenges exist to assigning LoT in a uniform way. The
first of these is a lack of standard definitions and terminology. In
addition, it is not always clear which therapies should be assigned
a LoT. Furthermore, no standard format exists for expressing LoT
in a way that would succinctly convey multifaceted, complex and
clinically relevant information. There is, therefore, a lack of uniform
methodology for enumerating LoT in patients with solid cancers
and, in the absence of standard guidelines, clinicians and
investigators often apply their own interpretation, resulting in
variability and potential mis-classification,13 thereby hindering
both clinical care and research.
In this article, we provide our perspective on a systematic
and comprehensive framework to determine LoT in a
uniform manner, such that it is applicable to most common
clinical scenarios across solid malignancies. We begin by
defining key terms that are required to determine the LoT
(see Table 1). Next, we consider the complex issue of which
therapies should constitute a LoT and how they should be
characterised. Finally, we propose a novel and standardised
format for reporting LoT.
Our proposed framework relies on many terms and concepts
that are used only for solid cancers (such as ‘local/metastatic’,
Table 1. Definitions of key terms.
Term Definition
Anti-cancer agent A (bio)pharmaceutical product used for the treatment of malignant disease, including—but not limited to—
cytotoxic, endocrine, targeted, immunotherapy (including vaccine and cell and gene therapy) and
radiopharmaceuticals (e.g. radioisotopes, radio-labelled monoclonal antibodies, radioactive microspheres) that
has been approved by the FDA and/or the EMA for treatment of any cancer.
Note: (1) An anti-cancer agent in clinical development not yet approved by the FDA and/or EMA for treatment
of any cancer (as on date of starting such therapy) should be termed an ‘experimental anti-cancer agent’; (2)
Supportive therapy (e.g. haematopoietics, drugs for preventing skeletal related events, etc) should not be
considered as an anti-cancer agent.
Anti-cancer modality The type of therapy used to remove, kill or suppress cancer cells, including:
• Surgery (therapeutic and including, but not limited to, open surgery, laparoscopic surgery, video-assisted
thoracic surgery, robot-assisted surgery, etc.), but excluding diagnostic biopsy;
• Radiotherapy (including, but not limited to, external beam radiation, brachytherapy, proton beam,
stereotactic radiosurgery) but excluding radiopharmaceuticals (e.g. radioisotopes, radio-labelled monoclonal
antibodies, radioactive microspheres);
• Systemic anti-cancer therapy (SACT; see definition below);
• Other (including, but not limited to, high-intensity focused ultrasound, cryotherapy, thermal ablation,
photodynamic therapy, hyperthermia, vascular embolisation and anti-cancer agents not meeting the
definition of SACT).
Clinical progression of disease (cPD) The clear worsening of the patient’s clinical status or prognosis in the opinion of the treating clinician, taking
into consideration clinical findings, imaging (including, but not limited to, objective imaging response criteria)
and laboratory test results.
Clinical setting The maximum extent of cancer spread experienced by the patient to date, denoted as
A: Early setting (operable, without known distant metastasis);
B: Locally advanced setting (inoperable, without known distant metastasis);
C. Metastatic setting (operable/inoperable, with known distant metastases)
Note: Operable implies that in the opinion of the clinician all known cancer can be completely removed
surgically; Inoperable implies that in the opinion of the clinician all known cancer cannot be completely
removed surgically.
Line of therapy (LoT) A serial chronological number assigned to each systemic anti-cancer therapy (SACT) and experimental SACT
administered to a patient and denotes a discrete attempt to treat the cancer.
Note: LoT is reported in the format LoT N (CLoT+ PLoT); CLoT is the number of SACT administered with
curative intent and/or in the early setting (i.e. operable, without known distant metastasis); PLoT is the number
of SACT given with palliative (i.e. non-curative/life-extending) intent and/or in the advanced setting (i.e.
inoperable and/or with known distant metastases); N is the sum of CLoT and PLoT.
Systemic anti-cancer therapy (SACT) SACT has the following features:
• It consists of one or more anti-cancer agents or experimental anti-cancer agents, which can be administered
alone or in combination or sequence (which might include alternating, hybrid, continuation maintenance
therapy and/or switch-maintenance therapy);
• It is prospectively planned;
• It is usually (but not necessarily) administered in repeating cycles;
• It is administered systemically, or via local/regional routes but with the intention of systemic effect or
significant reduction of overall tumour burden in the opinion of the clinician;
• It is given at a clinically relevant dose for a duration that is expected to exert systemic anti-cancer effect.
Note: (1) If the SACT is composed exclusively of experimental anti-cancer agent(s), the prefix ‘Experimental’
should be added to such SACT; (2) A patient participating in a study where the control arm consists only of a
placebo should not be considered to have received a SACT in that trial unless unblinded information is
available; (3) If an FDA/EMA-approved anti-cancer agent is used with the intention of providing supportive/
symptomatic care (e.g. dexamethasone is approved for multiple myeloma, but might also be used to treat
nausea and vomiting in patients with other cancers), it should not be considered as an SACT.
Treatment intent Treatment intent, in the opinion of the treating clinician, can be curative or palliative (i.e. non-curative/life-
extending)
(A) Curative therapy aims at complete elimination of cancer and preventing its recurrence;
(B) Palliative therapy aims at improving the quality and/or quantity of life but without the expectation of cure.
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‘operable/inoperable’, or ‘early/advanced’), and consequently is
not applicable to haematological malignancies.
A PROPOSED SYSTEMATIC AND COMPREHENSIVE
FRAMEWORK TO DETERMINE LOT
Terminology and definitions
In our definition of a LoT (see Table 1), a serial chronological
number is assigned to each administered SACT that denotes a
discrete attempt to treat the patient’s cancer. A SACT consists of
one or more anti-cancer agents, and can include alternating,14
hybrid,15 continuation maintenance16,17 or switch-maintenance
components.18 A SACT should be prospectively planned and well
defined. For example, a pre-planned sequence of platinum-based
chemotherapy followed by switch maintenance (which the
National Comprehensive Cancer Network defines as “…the
initiation of a different agent, not included as part of the first-
line regimen, in the absence of disease progression, after 4–6
cycles of initial therapy”)19 should be considered a single SACT.
Similarly, the pre-planned sequence of a conditioning/lympho-
depleting chemotherapy regimen followed by CAR-T cell transfu-
sion to a patient with synovial sarcoma constitutes a single
SACT.20 As another example, the systemic anti-cancer agents
embedded within a pre-planned sequence of neoadjuvant
chemotherapy, HER2-targeted therapy, surgery, radiotherapy,
and hormonal therapy for a patient with early breast cancer
should together be counted as a single SACT (see Table 2).
Although most anti-cancer agents are delivered orally or
intravenously, other routes—such as intramuscular, subcutaneous,
intrathecal, intraarterial, intraperitoneal, intravesical, intralesional,
cutaneous or intradermal—are also used,21 and the distinction
between the aim of local and systemic administration is not
always clear cut. In many situations, the aim of locally
administered anti-cancer agents is to generate a durable systemic
clinical response, as with the endocrine agent fulvestrant, which is
given intramuscularly in women with metastatic breast cancer. It is
also increasingly recognised that intratumoural injection of
immunotherapy can lead not just to local priming, but can also
have abscopal effects on distant tumours.22 Conversely, in other
clinical scenarios such as treatment of liver metastases,23 isolated
limb sarcomas,24 and other cases, the clinician might use anti-
cancer agents with the deliberate aim of obtaining a local/
regional, rather than systemic, effect. The development of
radiopharmaceuticals such as radioactive iodine-131, 177Lu-
dotatate and yttrium-90 has, to an extent, also blurred the
margins between systemic therapy and radiotherapy. Taking all
these scenarios into account, we define SACT as either being
administered systemically or by local/regional routes with the
intention of inducing a systemic effect or significantly reducing
overall tumour burden, in the opinion of the treating clinician.
Sometimes anti-cancer agents are administered at doses that
are substantially lower than usual—for example, when given
concomitantly with radiotherapy or as metronomic chemother-
apy; such treatment is frequently ‘off-label’. On other occasions,
patients might experience severe toxicity from a SACT so only a
small cumulative dose is administered; an extreme example could
be a patient experiencing an anaphylactic reaction, precluding
further use. To qualify for assignment of a LoT, the treating
clinician must be of the opinion that the patient has received the
anti-cancer agent(s) at a clinically relevant dose and duration that
could potentially exert an anti-cancer effect.
Clinical progression of disease (cPD) is a clear worsening of the
patient’s clinical status or prognosis in the opinion of the treating
clinician, taking into consideration clinical findings, imaging
(including, but not limited to, objective imaging response criteria)
and laboratory test results. While the clinician should align as far
as possible with the definition of progressive disease (PD) by
objective imaging response criteria,25,26 we propose that the term
cPD be used in the scenario in which the treating clinician is of the
opinion that a patient’s cancer is progressing but does not yet
meet the criteria for PD by objective imaging response criteria, or
if images are not available or evaluable. Conversely, a patient
might technically fulfil the criteria for PD by objective imaging
response criteria, but the clinician might be of the opinion that
this is not clinically relevant—for example, if the ‘baseline’ scan
was carried out some time before treatment started. The cPD
designation is especially relevant when SACT is administered in
routine practice in situations where objective imaging response
criteria do not always play a key role in decision making. Within a
clinical trial, cPD will usually equate to PD by objective imaging
response criteria; however, a patient with stable disease by
objective imaging criteria but ‘symptomatic deterioration’ would
be designated as having cPD. This reflects routine practice, and is
frequently accepted in clinical trials, but the cPD designation will,
we hope, add clarity.
Which treatments should be assigned a line of therapy?
Great heterogeneity exists in the literature and clinical trial
protocols regarding what constitutes a LoT. Some clinical trial
eligibility criteria allow prior systemic therapies for locally
advanced inoperable cancer to be counted as a LoT,27 while
others count SACT for distant metastases only;28 some criteria
require completion of all curative systemic therapy,29 while others
just require a certain number of prior SACTs irrespective of clinical
setting or intent.30,31
Anti-cancer treatments are often tailored to the extent of
disease, an approach termed ‘goal-concordant care’. For example,
in patients with breast cancer, the therapeutic approach to early
disease is distinct from that of metastatic disease, while therapy of
patients with inoperable locally advanced disease is often similar
to that of patients with disseminated malignancy.2,32 At present,
many clinicians and clinical trial protocols assign LoT only to SACT
for inoperable locally advanced or metastatic disease and/or when
the treatment intent is palliative. There are two key arguments
against this restrictive approach. First, the boundary between early
and advanced disease settings, and that between curative and
palliative intent, can be blurred. It is well-established that cancer is
a systemic disease, with a spectrum of increasing cancer burden
from small lesions in the primary organ to locally advanced
carcinoma to oligometastatic disease to widespread visceral
metastases (Fig. 1); the corresponding goals of anti-cancer therapy
range from cure through achieving durable remission to sympto-
matic relief at different time points in a patient’s journey.
Matching treatment intent to the extent of disease might be
straightforward in some scenarios, such as curative intent in the
early disease setting, but not in others. For example, the
development of multiple lung metastases would make the intent
of subsequent SACT palliative in a patient with breast cancer since
advanced breast cancer is believed to be incurable;2 however, if
the same clinical scenario of multiple lung metastases was seen in
a patient with seminoma, the intent may still be curative,33 given
the excellent chemosensitivity of this type of cancer. If a patient
with a limited number of liver metastases receives preoperative
chemotherapy followed by complete resection, some clinicians
and trial protocols would not count this as a ‘line’ of SACT in the
case of a colonic primary; by contrast, chemotherapy for treating
liver metastases would count as a LoT for a patient with breast
cancer. Hence, restricting LoT only to the advanced setting and/or
when used with palliative intent could lead to inconsistencies
among different solid cancers with regards to what should be
counted as a ‘line’. Even within the same tumour type, such as
breast cancer, therapy for locally advanced disease is counted as a
LoT in some studies,27 but not in others.28 Second, there is
evidence that the clinically meaningful benefit (such as objective
response rate and progression-free survival) of subsequent SACTs
decreases as the number of lines of prior SACT increases.34–38 It is
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reasonable to hypothesise that this inverse linear association
should also apply to the total number of such SACTs administered,
not just those given in the advanced/palliative setting. For
example, patients with early breast cancer who have residual
disease at surgery following neoadjuvant treatment,39 or who
develop isolated locoregional recurrence,40 often receive addi-
tional systemic therapy that might well have an impact on
subsequent therapeutic options and clinical outcomes, but such
treatment is not currently counted as a LoT by many clinicians and
trial protocols.
We propose that all SACTs, whether administered for early,
locally advanced, or metastatic cancer, be assigned a LoT. It could
be argued that local therapies including surgery, stereotactic
ablative radiotherapy,41 brachytherapy, external beam radio-
therapy, other methods of delivery of local energy (such as
high-intensity focused ultrasound, cryotherapy, thermal
ablation, photodynamic therapy, hyperthermia, etc.) and anti-
cancer therapies that don’t currently meet the definition of
SACT should also count as a LoT. For now, we propose that
they not be included as their impact on subsequent systemic
treatment choices is unclear, and to include them would
add complexity.
If a patient develops primary cancer in more than one organ,
the SACTs administered for each primary organ should be
separately assigned LoTs. For patients who develop a second
ipsilateral or contralateral cancer in paired organs such as the
breast, the clinician should continue serial numbering of LoT if
they consider it to be a locoregional recurrence from the initial
cancer; alternatively, they should start a separate record if they
consider it to be a new primary cancer.
Proposed standardised format for reporting lines of therapy
As mentioned above, the current method of reporting LoT with a
single ordinal number—for example, first-line metastatic—
although simple and widely used, is often imprecise, liable to
misinterpretation, and incomplete in capturing and expressing
nuanced information about the number of prior therapies.
We propose that prior LoT should be reported in a standardised
format as LoT N (CLoT+ PLoT), where CLoT is the number of
systemic regimens given with curative intent and/or in the early
setting (that is, operable, with no known distant metastasis), PLoT
is the number of systemic regimens administered with palliative
(that is, non-curative/life-extending) intent and/or in the advanced
setting (that is, inoperable and/or with known distant metastases),
and N is the sum of CLoT and PLoT. See Table 2 for an illustrative
example.
As previously discussed, the boundary between curative and
palliative intent, and also between advanced and early setting, can
sometimes be unclear, and the clinician should use their best
judgement and dichotomise a given LoT into CLoT or PLoT,
keeping in mind the type of cancer as well as individual patient
characteristics. The intent of the treatment should take prece-
dence in making this choice. In determining the LoT, the opinion
of the treating clinician should usually prevail.
NEXT STEPS
As a next step, multiple stakeholders from diverse backgrounds
and regions, including clinicians subspecialised in different cancer
types, informaticians, data scientists, patient advocates, regulatory
authorities and representatives of cancer centres, clinical trial
units, professional oncology societies, and contract research
organisations, should discuss these proposals in detail, including
the definition of standard dataset and guidelines, to facilitate their
widespread adoption. In this section, we provide our views as a
starting point for those discussions.
Standardised dataset
We propose a standardised template (Table 2) for recording data
that are critical for determining LoT. The adoption of such a
standardised minimum dataset for collecting and annotating
patient data would aid the uniform application of information
regarding LoT. Most of these data are already present in different
parts of the electronic health records (EHRs) and tabulating them
chronologically in a standard format could facilitate the easier
review of all SACT administered to a given patient.
The clinical setting and the treatment intent are required to
dichotomise a given SACT into either CLoT or PLoT. The date of
the most recent cPD is key for accurately enumerating LoT.
Recording all anti-cancer therapies would allow the entire
treatment history to be easily reviewed in chronological order.
Additionally, the temporal sequence (e.g. chemotherapy followed
by surgery) or combination of approaches (e.g. chemotherapy and
radiation therapy) could provide insights into treatment intent.
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Fig. 1 Over time, as a patient’s cancer burden increases, the corresponding goals evolve, and anti-cancer treatment is accordingly
customised to provide goal-concordant care. Line of therapy (LoT) should be reported in a standard format as LoT N (CLoT+ PLoT). The
distinction between CLoT (curative intent and/or early setting) and PLoT (palliative intent and/or advanced setting) could be unclear in some
scenarios, and the clinician should make a considered decision keeping in mind the type of cancer as well as individual patient characteristics.
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The use of a standardised dataset would yield several
advantages. First, it would allow us to identify patients for specific
trials more easily. For example, potential participants for a study
requiring patients who have received ‘…no more than two
separate lines of treatment for metastatic colorectal cancer’
(irrespective of the treatment intent)42 could be identified by
counting all SACTs where the clinical setting option ‘Metastatic
(Operable/inoperable, with known distant metastases)’ has been
selected as the option (see footnotes to Table 2). As another
example, if a protocol states that prior SACT given in the early
setting should be counted as having been given for advanced
disease if the disease-free interval is of less than a specified
duration,43 these patients could be identified from the interval
between the stop date in a given row and date of cPD in the next
row. This dataset, which summarises patient treatment in a single
table, would help referrals by use of a familiar and standard
template. Also, when a patient being treated at a hospital enters a
clinical trial, the investigators could authorise their local EHR to
directly auto-populate (under secure and compliant systems) the
trial database with the redacted dataset related to prior lines of
therapy, thus reducing effort and errors.
Importantly, this uniform characterisation of LoT would facilitate
the auditing of SACT, which is an area of increasing interest. For
example, in the UK, the SACT dataset collects systemic anti-cancer
therapy prescriptions from all NHS England providers and aims to
allow better understanding of treatment patterns and outcomes
on a national scale.3 The UK database does not, however,
characterise LoT as comprehensively as the current proposal
would do.
Widespread consultation among key stakeholders should take
place to establish a consensus on a standardised dataset that
could make LoT determination easier, more uniform, and quicker,
and subsequently embed it within hospital prescribing systems
and EHRs. It might be possible to use such a standardised dataset
in the form of an electronic spreadsheet with drop-down menus,
in a form that can interface with other databases, or even in a
paper format.
Standardised guidelines to assess LoT
The development of standardised guidelines for enumerating LoT
—applicable to all solid cancers—should be a key endeavour of
the oncology community. Counting LoT is straightforward and
non-controversial in many common clinical scenarios; draft
guidelines for these are presented in Table 3. Developing broadly
acceptable guidelines for some other clinical situations, such as
handling unplanned changes in SACT in the absence of cPD, and if
LoTs should be assigned to radiotherapy or surgery, could prove
to be more difficult; such scenarios need to be discussed with key
stakeholders in order to evolve a consensus. For example, if an
anti-cancer agent is discontinued due to toxicity and substituted
by another agent of a different class, should the same LoT be
retained? Financial considerations can be important factor in
cancer therapy,44 so if the use of a SACT is stopped for financial
reasons only and substituted with another, should that be
assigned a new LoT? If a perimenopausal woman attains
biochemical menopause while on tamoxifen for metastatic breast
cancer and her treatment is changed to an aromatase inhibitor in
the absence of cPD or toxicity, should these be counted as
separate lines? Should rechallenge45,46 or retreatment47 be
assigned a new LoT when it is not part of a pre-planned
alternating, hybrid, continuation maintenance or switch-
maintenance therapeutic plan? What impact, if any, should a
‘drug holiday’ have on numbering subsequent LoT?
Discussions based on the Delphi method of consensus
development and/or benchmarking studies should take place to
establish agreement on a standardised set of comprehensive
guidelines for LoT determination. Such broader testing for
acceptability within the oncology community is necessary, and
we propose to continue working in this direction, along with other
experts and stakeholders.
CONCLUSION AND DISCUSSION
We propose a simple, comprehensive, and reproducible frame-
work consisting of common definitions, standardised dataset, a
novel recording format, and standard guidelines for determining
LoT. This framework is applicable to the majority of commonly
encountered clinical and research scenarios in patients with solid
cancers and can be applied to prospective, contemporaneous or
retrospective recording and determination of lines of prior anti-
cancer therapies. This proposal should form the basis for wider
discussions with a view to optimisation, validation and subse-
quent broad adoption.
The extraordinary diversity in the clinical manifestations of
cancer as well as the tremendous complexity of its treatment pose
huge challenges in formulating general criteria or guidelines that
are applicable across all (or most) types of solid cancer; notable
exceptions/successes include tumour staging (TNM), performance
status (PS), the common terminology criteria for adverse events
(CTCAE) and the response evaluation criteria in solid tumours
(RECIST and iRECIST). It has, however, proved difficult to
consistently and reproducibly enumerate the prior LoT adminis-
tered to patients with cancer, for several reasons, including the
complexity of therapy, which includes multiple phases and
settings, as well as planned and unplanned gaps in its
administration; to date, standard guidelines for determining LoT
are available only for patients with multiple myeloma.11
Definitions of LoT vary widely, which has implications for trials
and clinical practice. For example, an analysis by researchers from
the University of Oxford of cancer drug appraisals by the UK
National Institute for Health and Care Excellence highlighted that
the population recruited to cancer trials does not always precisely
match the licenced indication for the anti-cancer agent being
evaluated, with disparities related to specific line of treatment as
Table 3. Draft guidelines for determining lines of therapy in patients with solid cancers.
(1) Once clinical progression of disease (cPD) is documented, assign a new line of therapy (LoT) to the next systemic anti-cancer therapy (SACT).
(2) In the absence of cPD, if an anti-cancer agent that is part of a SACT is discontinued due to toxicity and substituted by another anti-cancer agent of
the same class, retain the same LoT.
(3) In the absence of cPD, if one or more new anti-cancer agent is added to an ongoing SACTa consider this a new SACT, and assign it a new LoT
(4) Irrespective of cPD, if one or more anti-cancer agent is discontinued from an ongoing SACT for any reason, retain the same LoT for the remaining
anti-cancer agents.
(5) Irrespective of cPD, if the dose or schedule or route of administration of one or more anti-cancer agent of an ongoing SACT is modified for any
reason, retain the same LoT.
aExcept if prospectively planned per definition of SACT in Table 1, and except in scenario covered above in Guideline No. 2.
Determining lines of therapy in patients with solid cancers: a proposed. . .
KS Saini and C Twelves
6
well as prior drug exposure, indication under consideration,
specific mutation, and cancer type.13
A greater level of uniformity is valuable in improving the quality
of any system, including complex health systems,48 and one way
this can be achieved is by harmonising nomenclature, definitions
and methodologies.49–52 In addition to benefits with relevance to
clinical trials, regulatory approvals and re-imbursement, our
proposed format for documenting LoT captures multifaceted data
in a standardised manner. This could allow those data to be
analysed in nuanced and clinically relevant ways, leading to the
creation of searchable institutional databases that allow auto-
mated queries to identify specific patient populations for auditing
or clinical trial participation, facilitating cross-trial comparison of
data, and enabling more accurate meta-analyses.
The documentation relating to clinical practice and research in
patients with cancer is already burdensome.53 Some data
elements proposed in this article would need to be provided by
the clinician who prescribed the anti-cancer therapy, or a suitably
trained delegate such as a clinical trainee or oncology nurse. It is
our hope that the proposed standard dataset and the uniform LoT
N (CLoT+ PLoT) format will ultimately reduce the overall burden
by simplifying and standardising the collection of treatment and
LoT data.
We acknowledge that our proposed framework for determining
LoT does not, at this time, cover all possible clinical scenarios and
that differences of opinion with some elements might arise.
Considering the complex real-world challenges in healthcare and
the heterogeneity of the information systems across and within
countries, it remains to be seen how quickly our proposal is
adopted at least in referral academic cancer centres, and how
widely applicable it eventually proves to be.
In dealing with the enormous complexity of this subject, we
were guided by Simon’s principle of ‘satisficing’; namely, that we
can either find optimum solutions for a simplified world, or
satisfactory solutions for a more realistic world.54 We have opted
for the latter, which we judge appropriate given the ever-
increasing complexity of cancer care. Remaining questions include
whether locoregional treatments given with the intent of treating
local disease alone, including radiotherapy and surgery, should
also count towards LoT. Likewise, although we propose guidelines
for enumerating LoT in most common scenarios, there remain
issues for further discussion around assigning LoTs, especially
around unplanned changes to SACT in the absence of cPD.
Imminent next steps would include the commencement of broad-
based discussion with colleagues, experts, and stakeholders to
evolve a consensus on the standardised dataset and guidelines to
be used for determining LoT, which could then be piloted in one
or more cancer centres using retrospective chart review. Lessons
learnt from this exercise could then be applied when evaluating
the use of the guidelines in patients with a broader range of solid
cancers in more diverse settings where cancer services and trials
are delivered.
In the future, artificial intelligence (AI) solutions might be able to
accurately determine LoT directly from EHRs. Machine-learning
algorithms that are currently being developed to estimate the
number of LoT mainly rely on drug names, dose, repetition,
cadence and other such objective measures8,55,56 but these are
not ready for prime time use. There is, therefore, a need for a
practical solution that can be implemented at pace and scale.
Moreover, AI solutions for LoT assignment would probably be
accelerated by the adoption of the standard definitions, dataset,
novel recording format, and guidelines that we propose.
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